Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Share-based Compensation: 2018-2024

Historic Share-based Compensation for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to $79.2 million.

  • Revolution Medicines' Share-based Compensation rose 48.15% to $30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.1 million, marking a year-over-year increase of 30.35%. This contributed to the annual value of $79.2 million for FY2024, which is 28.21% up from last year.
  • Latest data reveals that Revolution Medicines reported Share-based Compensation of $79.2 million as of FY2024, which was up 28.21% from $61.8 million recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Share-based Compensation ranged from a high of $79.2 million in FY2024 and a low of $8.9 million during FY2020.
  • In the last 3 years, Revolution Medicines' Share-based Compensation had a median value of $61.8 million in 2023 and averaged $57.4 million.
  • Data for Revolution Medicines' Share-based Compensation shows a peak YoY spiked of 181.11% (in 2020) over the last 5 years.
  • Over the past 5 years, Revolution Medicines' Share-based Compensation (Yearly) stood at $8.9 million in 2020, then spiked by 133.22% to $20.7 million in 2021, then spiked by 50.53% to $31.2 million in 2022, then spiked by 98.01% to $61.8 million in 2023, then rose by 28.21% to $79.2 million in 2024.